ArticleCancer reports (Hoboken, N.J.)2025
Acetyl Salicylic Acid, COX-2 Inhibitors and Other NSAIDs and Breast Cancer Survival in a Finnish Population-Based Cohort.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Acetyl Salicylic Acid, COX-2 Inhibitors and Other NSAIDs and Breast Cancer Survival in a Finnish Population-Based Cohort.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundNon-steroidal anti-inflammatory drugs (NSAIDs), particularly acetylsalicylic acid (ASA), have been associated with reduced breast cancer (BCa) mortality. While overexpression of cyclooxygenase-2 (COX-2) correlates with poorer prognosis in BCa, COX-2 inhibitors (coxibs) have not demonstrated a survival advantage. However, the evidence remains conflicting and limited. We examined associations between BCa mortality and NSAID use in a Finnish population-based cohort.
methodsThe study cohort, 73 170 women with new BCa diagnosis during 1995-2013 was identified from The Finnish Cancer Registry. Follow-up data including date and the cause of death, NSAID purchases from 1995 to 2015, mammography screening participation and tumor hormone receptor status, were obtained from national registries. NSAID purchases were categorized into NSAIDs overall, ASA, and coxibs. BCa-specific and overall survival by NSAID use were analyzed using Cox proportional hazard regression, adjusted for age, tumor extent, primary treatment, Charlson comorbidity index, hypertension, diabetes, mammography participation, and hormonal therapy.
resultsPre-diagnostic use of NSAIDs (HR 0.78, 95% CI: 0.75-0.81) and coxibs (HR 0.76, 95% CI: 0.71-0.81) was associated with reduced BCa mortality, while ASA showed no association. Post-diagnostic NSAID use was associated with increased BCa mortality (HR 1.27, 95% CI: 1.22-1.33), while ASA use (HR 0.84, 95% CI: 0.73-0.97) showed dose-dependent risk reduction.
conclusionPost-diagnostic use of ASA is associated with reduced BCa-specific mortality, distinguishing ASA from other NSAIDs. Clinical trials are required to determine the ideal ASA dose, frequency, and duration for treating BCa. Pre-diagnostic use of NSAIDs overall is associated with a slight reduction in BCa mortality without dose dependence. The potential role of pre-diagnostic NSAID use as a prognostic factor in BCa warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.